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Summary Flavone acetic acid (FAA) is a compound with proven activity against various transplantable
colon cancers in mice. In this study it was evaluated against primary colon tumours, chemically induced by
methylazoxymethanol in outbred CF1 mice. FAA was given i.v. at doses of 70 or 100 or 150mgkg-1 every 7
days for 6 weeks. Only 4 out of 60 FAA treated mice died of toxicity. FAA reduced tumour number and
tumour burden compared to control mice (P<0.05 at least), with no apparent dose-response relationship. Anti-
tumour activity of FAA was comparable to that of 5-fluorouracil (5-FU) used as standard. Moreover, FAA
was more effective that 5-FU against large tumours. FAA levels in plasma and different tissues (including
colonic neoplastic lesions) after a single i.v. dose of 150mgkg-1 were investigated. Tumour FAA levels
appear insufficient to be responsible for the antitumour activity based only on a direct FAA cytotoxic effect.
The results confirm clinical interest in FAA and suggest that mechanisms other than direct cytotoxicity may
be involved in its activity.
Flavone acetic acid (FAA, NSC 347512, LM 975) has been
recently identified as a potential new antitumour drug. It
was selected largely on its activity against mouse colon
adenocarcinoma 38, which responds weakly to available
anticancer drugs (Plowman et al., 1986; O'Dwyer et al.,
1987). Successively Corbett et al. (1986) demonstrated
significant activity on a large spectrum of transplantable s.c.
tumours of mouse, including various colon tumours. It is
still questionable, however, whether these s.c. transplantable
tumours are adequate models to predict the activity of drugs
for human colon adenocarcinomas. Murine primary chemi-
cally induced colon tumours reproduce the clinical situation
with respect to their natural history, their original tumour-
host interaction and their low chemosensitivity to clinically
used drugs. A methylazoxymethanol (MAM) induced prim-
ary colon adenocarcinoma model, suitable for chemotherapy
studies (Pratesi & Deschner, 1984), has been recently
described.
In the present study we evaluated the activity of FAA on
MAM induced colon tumours and the drug distribution in
tumour bearing mice.
Materials and methods
Animals
Outbred female CF1 mice, from Charles River Laboratories,
USA, were used. They were received when 6-7 weeks old
and maintained on chow and water ad libitum, in a
controlled environment throughout the study.
Tumour induction
The experimental model has been described in detail else-
where (Pratesi & Deschner, 1984). Briefly, the mice were
injected s.c. once a week for 10 weeks with MAM (Janssen
Chimica, Belgium), at a dose of 0.4mg/mouse. After 20
weeks, a few randomly selected mice were killed weekly and
their colonic mucosa wa macroscopically inspected for
lesions.
Drugs and treatment
Flavone acetic acid (FAA, received from NCI, USA, by
courtesy of Dr M.K. Wolpert) was dissolved in 3% bi-
carbonate solution. 5-Fluorouracil (5-FU, clinical prep-
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aration from Roche, Italy) diluted in sterile water was used
as standard compound. Drugs were administered i.v. once a
week for 6 weeks, in a volume of 10mlkg-1 body weight
(except for the dose of 150mgkg-1 FAA which was given in
15mlkg-1). Drug treatment started 23 weeks after the first
MAM injection since at this time all mice were assumed to
have tumours in the colonic mucosa. Some tumour-bearing
animals, with intestinal obstruction, resulting in emaciation
were excluded from the experimental groups. One week after
the last drug treatment, all animals were killed by cervical
dislocation. The organs were removed and placed in 10%
neutral buffered formalin. Each large intestine was opened
longitudinally and macroscopic tumours were counted
(tumour number=TN). Mice without visible tumours were
considered as TN 0. The volume of each tumour was
calculated from caliper measurements as the product of the
three dimensions, in mm3. The total tumour burden (TTB)
was the sum of the single tumour volumes for each mouse.
Average values (+s.e.) of TN and TTB for each group were
calculated and the ratio of the value in treated (T) over
control mice (C) x 100 was estimated (T/C %). Few mice
died during the experiment and were not included in these
calculations.
Pharmacokinetic studies
CF 1 female mice, 30 weeks after the first MAM injection,
were given an i.v. dose of 150mgkg-' FAA. Animals were
killed 30, 60, 120min after treatment. At each time, plasma
and tissues (liver, kidney, spleen, tumour and colon, after
excision of in situ tumours) were collected separately from 4
animals. All samples were frozen immediately at -200 until
analysis.
FAA was quantified by a modification of the HPLC
method of Double et al. (1986). Briefly, 100p1 plasma were
added to 0.5mlH20, 200,u1 5% TCA and lOOpl flavone 8-
propionic acetic acid as internal standard (kindly provided
by Dr Nardi, Recordati, Italy). FAA was extracted with
chloroform:isopropanol (1:1) and then mixed at room tem-
perature for 1 h.
The precipitate and aqueous phase were sedimented by
centrifugation for 15min at 3000 rpm. The organic layer
was then removed and dried under vacuum. The samples
were resuspended in 200-400l1 methanol. Tissues were
homogenized in water (liver 1:10 and other tissues 1:2) and
1 ml of the liver homogenate or the whole specimen for the
others was processed as for plasma. Extracts were injected
into a Waters Model 6000 A HPLC equipped with UV
detector, set at 254nm. Separation was performed using an
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Table I Effect of FAA and 5FU on MAM-induced colon tumours in CFl mice at 29 weeks
Compounda Evaluated miceb A weightc Tumour Number Total tumour burden (15Omgkg-') Total mice (grams) Average+s.e. %T/C Average+s.e. %T/C
Controls 22/22 +0.6 7.8+0.9 268+45
FAA 70 18/20 +0.1 5.0+0.1 64d 109+22 41e
100 19/20 0 4.2+0.9 53f 108+26 40f
150 19/20 +0.1 4.7+ 1.1 61C 140+33 52e
5FU 52 22/23 0 4.3+0.8 55f 145 +30 54e
'Drugs were delivered i.v. once a week for 6 weeks starting 23 weeks after the first MAM injection; bMice that died before the 29th week were not included; cDifference between the mean weight of mice before and after the 6 drug treatments; dP<0.1; ep<o.05; 'P<0.01 compared to control mice.
isocratic solvent system of 0.001 M phosphoric acid:aceto-
nitrile:ethanol (60:30:10) at a flow rate of 1 mlmin-1 with a
C18 uBondapak column (Waters Assoc., New York, NY,
USA). Recovery was 95% and sensitiviy was respectively
lOOngml-1 and 200ngg-1 for plasma and tissue samples.
The curve was linear in the range 0.01-40pgml-1; CV=
0.8%.
Statistical analysis
The Mann-Whitney rank test (two tailed) was used for
statistical comparison of TTB and TN values in treated and
control mice (Table I). The X-square test was used to
compare the number of mice bearing <5 and >5 or more
tumours in treated and in control groups (Table II).
Results
FAA significantly reduced TN and TTB at all three doses
tested (Table I). In the range of doses used, no clear dose-
response relationship was observed, TN and TTB values not
being statistically different after 70, 100 or 150mgkg-1. At
the doses administered, FAA did not cause severe toxicity,
only 4 out of 60 mice treated wtih the three doses died
before the end of the experiment, and weight loss was not
observed.
5-FU at its maximum tolerated dose of 52mgkg-1
(Pratesi et al., 1987) achieved 55% T/C for TN and 54%
T/C for TTB (P<0.01 and P<0.05, respectively). Tumour
inhibition was comparable to that attained by FAA.
Table II shows, for each experimental group, the distribu-
tion of mice based on the number of tumours (less than or
at least five) found at the end of the experiment. Both FAA
and 5-FU treatments significantly reduced the number of
tumours.
The distribution of tumours based on their volume is
reported in Table III. In the control group or in 5-FU
treated mice, 6 and 10% of tumours were > lOOmm3
respectively, whereas in FAA treated mice they were only 1-
3% of the total number. The low frequency of large tumours
in each FAA treated group makes a statistical comparison
with the control group difficult. However when tumours
larger than 100 mm3 in FAA treated mice were pooled
together regardless the dose (5 tumours out of 260) a
statistically significant difference (P<0.05 by X-square test)
was achieved vs. control mice (10 out of 171) and vs. 5-FU
treated mice (9 out of 94).
Table IV summarizes FAA levels in plasma and tissues at
different intervals after an i.v. dose of 150mgkg-1. Drug
levels were highest in liver and kidney, lower and similar in
tumour, colon and spleen. Though obviously three points are
not sufficient for an accurate estimate of pharmacokinetic
parameters, FAA plasma half-life was 90min. The rates of
disappearance from tissues and plasma were very similar.
Table II Distribution of mice based on number of tumours at 29
weeks
No. of mice bearing
Compound <5' tumours 5 tumours
(mgkg-1) No. of mice (%) (%) <
Controls 22 6 (27) 16 (73)
FAA 70 18 10 (56) 8 (44) 0.1
100 19 13 (68) 6 (32) 0.01
150 19 13 (68) 6 (32) 0.01
5FU 52 22 15 (68) 7 (32) 0.01
aIncluding mice without tumours.
Table III Distribution of tumours based on their
volume at 29 weeks
Tumour volume (mm3)
100 >100
Compound Total
(mgkg l) No. (%) No. (%) number
Controls 161 94 10 6 171
FAA 70 89 99 1 1 90
100 79 99 1 1 80
150 87 97 3 3 90
5FU 52 85 90 9 10 94
Table IV Mean plasma (pgml - and tissue (pgg-1) levels
(±s.e.) of FAA after i.v. injection of 150mgkg-1 in CFI
mice
30mina 60min 120min
Plasma 201 +29 140+32 57+ 15
Liver 174+ 4 130+25 55+ 14
Kidney 193+12 159+14 75+ 4
Spleen 83+ 7 58+ 7 18+ 5
Colon 108+14 73 + 9 23+ 3
Tumour 133+25 45+23 19+ 8
aGroups consisted of 4 mice at 30 and 60min, and of 3
mice at 120min.
Discussion
In the present study FAA reduced the number and burden
of primary colonic tumours induced by MAM in mice. In
previous in vivo studies evaluating the toxicity of FAA, the
maximum cumulative tolerated dose was around
600mgkg-1 for a treatment period up to 20 days (Corbett et
al., 1986). In this study, a higher total dose could be given to
mice in a longer period: in fact FAA doses up to
900mgkg- (150mgkg-1 for 6 times, weekly) were very well
tolerated by all animals.
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In previous studies, the FAA doses that showed significant
antitumour activity were very close to the toxic ones
(Corbett et al., 1986). In contrast, in the experimental model
we used, the antitumour effects of 70, 100 and 150mgkg-1
repeated doses were similar. Previous studies, however,
employed s.c. transplanted tumours, whereas we investigated
FAA activity in chemically induced tumours which grow in
the colonic mucosa. We wonder whether the high suscepti-
bility of MAM-induced tumours even to doses much lower
than the toxic ones, might depend on their localization. The
pharmacokinetic outline obtained however, does not indicate
a preferential drug distribution in the colon tumours, where
the FAA concentration was similar to or lower than that in
other, normal tissues. Moreover in vitro studies on colon
carcinoma cell lines showed growth inhibition at FAA
concentrations greater than 400Mgml-1 for at least 24 hours
(Bibby et al., 1987; Capolongo et al., 1987) and the FAA
levels achieved in these primary tumours of mice after a dose
of 150mgkg-1 appear to be too low to explain the observed
tumour inhibition based only on a direct FAA cytotoxic
effect. This reasoning is even more convincing when it is
considered that doses of 70 and 100mgkg-1 were also
effective against these tumours and presumably resulted in
even lower FAA tumour concentrations.
Since the antitumour effects of FAA may be mediated by
natural killer (NK) lymphocytes (Wiltrout, 1987; Ching &
Baguley, 1987) and very high NK activity has been described
in the murine gastrointestinal tract (Tagliabue et al., 1981),
these reasons could explain the effects achieved by FAA
against primary colon tumours. A site-dependent sensitivity
of tumours to FAA effects has already been reported by
Double et al. (1987) and Giavazzi et al. (1988). In the former
paper, the murine colon MAC 15 tumour responded to FAA
when growing s.c. and not when cells were injected i.v. or
i.p. In the latter study, a human colon tumour xenograft,
virtually insensitive when growing s.c., was extremely sensi-
tive to FAA when growing in the liver after intrasplenic
injection. No definitive explanations for these discrepancies
have been reported by either authors.
In the present study, a lower number of large tumours was
found in FAA treated mice than in untreated control mice.
Even though this observation should be supported by more
detailed studies, FAA seems more effective against large
than against small neoplastic lesions. This is unusual for an
anticancer agent, but could be in keeping with the recent
proposed hypothesis that FAA acts much the same way as
tumour necrosis factor (TNF) (Smith et al., 1987) and, like
TNF, may be more effective on more advanced tumours
(Manda et al., 1987).
In conclusion, our study provides evidence that FAA is
certainly effective against primary murine colon tumours,
confirming the results against murine transplantable
tumours. Moreover, mechanisms of action other than a
direct cytotoxicity seem to be involved in its activity on
murine models. Until now, however, no responses have yet
been seen in early clinical investigation and this observation
might reflect some fundamental difference between the way
FAA actos in man and mouse. A better knowledge on
mechanism of action of FAA might be needed as a basis for
appropriate clinical investigations.
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